ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. - Seow J; Graham C; Hallett SR; Lechmere T; Maguire TJA; Huettner I; Cox D; Khan H; Pickering S; Roberts R; Waters A; Ward CC; et al. (Cell reports, 2022)